Program
lebrikizumab
Also written as “Lebrikizumab”, “lebrikizumab (MILR1444A)” and “LY3650150”.
Its studies are mostly in Dermatitis, Atopic · Asthma · Nasal Polyps · Rhinitis, Allergic, Perennial · Pulmonary Disease, Chronic Obstructive, led by 4 companies.
Drug pageLebrikizumab: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 194 open or running | phase 4since May 28, 2025 | Feb 16, 2018 | May 2027phase 3 · NCT06338995 |
| Hoffmann-La Roche | 180 open or running | phase 3since May 29, 2013 | Oct 27, 2008 | none ahead |
| Almirallits history only | 63 open or running | phase 3since Nov 26, 2021 | Nov 26, 2021 | Apr 25, 2027phase 3 · NCT06526182 |
| Tanoxits history only | 10 open or running | phase 2since May 17, 2006 | May 17, 2006 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Oct 27, 2008.
- Aug 22, 2011Phase 1 study in Healthy VolunteerNCT01423318 · 60 enrolled · United States
- Mar 1, 20122 phase 2 studies in AsthmaNCT01545453, NCT01545440
- May 29, 20132 phase 3 studies in AsthmaNCT01867125, NCT01868061
- Jun 5, 2013Phase 2 study in Idiopathic Pulmonary FibrosisNCT01872689 · 505 enrolled · United States, Australia, Belgium and more
- Jun 7, 2013Phase 3 study in AsthmaNCT01875003 · 346 enrolled · United States, Argentina, Brazil and more
- Nov 12, 2013Phase 2 study in AsthmaNCT01987492 · 230 enrolled · United States, Australia, Belgium and more
- Mar 26, 2014Phase 3 study in AsthmaNCT02104674 · 313 enrolled · United States, Brazil, Bulgaria and more
- Mar 26, 2014Phase 2 study in AsthmaNCT02099656 · 64 enrolled · United States, Canada, France and more
- Jan 13, 2015Phase 2 study in Dermatitis, AtopicNCT02340234 · 212 enrolled · United States, Australia, Canada and more
- Jun 4, 2015Phase 2 study in Dermatitis, AtopicNCT02465606 · 55 enrolled · United States, Canada
- Jun 29, 2015Phase 1 study in Healthy VolunteerNCT02486809 · 176 enrolled · United States
- Sep 7, 2015Phase 3 study in AsthmaNCT02546869
- Sep 9, 2015Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT02546700 · 309 enrolled · United States, Argentina, Bulgaria and more
- Nov 10, 2026Phase 2 study terminatedStudy stoppedNCT01987492 · “Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.”
TargetBeta
“A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities”NCIt, by rule
“Interleukin-13 inhibitor; Interleukin-13 inhibitor”ChEMBL 37, by rule
Other programs on IL13
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tilrekimig | Pfizer | phase 3 | 11 |
| lunsekimig | Sanofi | phase 3 | 10 |
| zumilokibart | AbbVie | phase 2 | 4 |
| ompekimig | Pfizer | phase 2 | 3 |
| GHZ339 | Novartis | phase 2 | 1 |
| ABBV-313 | AbbVie | phase 1 | 1 |
Studies
All 18 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02546700Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more | 2 | Completed | Nov 25, 2016 | 309 |
| NCT02546869Asthma | 3 | Withdrawn | Jun 29, 2016 | 0 |
| NCT02486809Healthy Volunteer · United States | 1 | Completed | Oct 2015 | 176 |
| NCT02465606Dermatitis, Atopic · United States, Canada | 2 | Completed | May 30, 2016 | 55 |
| NCT02340234Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Completed | Apr 2016 | 212 |
| NCT02104674Asthma · United States, Brazil, Bulgaria and more | 3 | Completed | Jan 22, 2016 | 313 |
| NCT02099656Asthma · United States, Canada, France and more | 2 | Completed | Oct 13, 2016 | 64 |
| NCT01987492Asthma · United States, Australia, Belgium and more | 2 | Terminated | Dec 19, 2016 | 230 |
| NCT01875003Asthma · United States, Argentina, Brazil and more | 3 | Terminated | Dec 28, 2016 | 346 |
| NCT01872689Idiopathic Pulmonary Fibrosis · United States, Australia, Belgium and more | 2 | Completed | Jul 28, 2017 | 505 |
| NCT01868061Asthma · United States, Argentina, Australia and more | 3 | Completed | Jan 2, 2017 | 1,068 |
| NCT01867125Asthma · United States, Argentina, Australia and more | 3 | Completed | Dec 28, 2016 | 1,081 |
| NCT01545453Asthma · United States, Australia | 2 | Completed | Jul 2013 | 205 |
| NCT01545440Asthma · United States, Australia | 2 | Completed | Mar 2013 | 258 |
| NCT01423318Healthy Volunteer · United States | 1 | Completed | Feb 2012 | 60 |
| NCT00971035Asthma | 2 | Completed | Dec 2010 | 210 |
| NCT00930163Asthma | 2 | Completed | Jul 2010 | 218 |
| NCT00781443Asthma | 2 | Completed | Nov 2009 | 29 |
How it is read
Names in the registry
- “Lebrikizumab”, 37 entries
- “lebrikizumab”, 7 entries
- “lebrikizumab (MILR1444A)”, 5 entries
- “LY3650150”, 2 entries
- “TNX-650”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 21 studies
- Asthma, 12 studies
- Nasal Polyps, 1 study
- Rhinitis, Allergic, Perennial, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.